Citigroup’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-36,900
| Closed | -$125K | – | 7965 |
|
|
2018
Q3 | $125K | Buy |
36,900
+6,000
| +19% | +$21.6K | ﹤0.01% | 5692 |
|
|
2018
Q2 | $116K | Sell |
30,900
-2,100
| -6% | -$10.2K | ﹤0.01% | 5583 |
|
|
2018
Q1 | $135K | Buy |
33,000
+16,500
| +100% | +$76.8K | ﹤0.01% | 5340 |
|
|
2017
Q4 | $77K | Buy |
16,500
+900
| +6% | +$4.96K | ﹤0.01% | 5865 |
|
|
2017
Q3 | $111K | Sell |
15,600
-11,400
| -42% | -$82K | ﹤0.01% | 5486 |
|
|
2017
Q2 | $195K | Buy |
27,000
+4,000
| +17% | +$25K | ﹤0.01% | 4813 |
|
|
2017
Q1 | $142K | Sell |
23,000
-22,300
| -49% | -$122K | ﹤0.01% | 4945 |
|
|
2016
Q4 | $265K | Buy |
45,300
+11,200
| +33% | +$61.2K | ﹤0.01% | 5046 |
|
|
2016
Q3 | $181K | Buy |
34,100
+12,300
| +56% | +$66.3K | ﹤0.01% | 4735 |
|
|
2016
Q2 | $144K | Buy |
21,800
+15,700
| +257% | +$87.8K | ﹤0.01% | 4791 |
|
|
2016
Q1 | $28K | Sell |
6,100
-4,100
| -40% | -$16.4K | ﹤0.01% | 6406 |
|
|
2015
Q4 | $52K | Sell |
10,200
-3,500
| -26% | -$16.6K | ﹤0.01% | 5922 |
|
|
2015
Q3 | $48K | Sell |
13,700
-1,000
| -7% | -$6.7K | ﹤0.01% | 5468 |
|
|
2015
Q2 | $147K | Buy |
+14,700
| New | +$158K | ﹤0.01% | 4700 |
|
Citigroup's KERX Position: Q4 2018 in Review
Citigroup sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 232,013 shares — an estimated $789K sold.
Citigroup first reported a position in KERX in Q2 2013 and held it in 22 quarters. The position peaked at $789K in Q3 2018. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Citigroup reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Citigroup sold 232,013 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $789K.
- Citigroup first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 22 quarters.
- Citigroup's Keryx Biopharmaceuticals Inc position peaked at $789K in Q3 2018.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Citigroup's 13F filing for Q4 2018, filed 12 Feb 2019.